CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Soleno Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Soleno Therapeutics Inc
203 Redwood Shores Parkway, Suite 500
Phone: (650) 213-8444p:650 213-8444 REDWOOD CITY, CA  94065  United States Ticker: SLNOSLNO
Business Summary
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Ernest B.Mario 84 2/1/2014 8/3/2007
President, Chief Executive Officer, Chief Operating Officer, Director AnishBhatnagar 55 1/1/2019 1/1/2006
Chief Financial Officer James H.Mackaness 59 11/1/2020 11/1/2020
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
SOLENO THERAPEUTICS UK LTD GARDEN COTTAGE BADGEMORE PARK HENLEY-ON-THAMES UK
SOLENO THERAPEUTICS EUROPE LIMITED SUITE 10151 26 UPPER PEMBROKE STREET Ireland
Essentialis, Inc. 7915 Corte Cardo Carlsbad CA United States

Business Names
Business Name
Essentialis, Inc.
SLNO
Soleno Therapeutics Europe Ltd.
Soleno Therapeutics U.K. Ltd.
Soleno Therapeutics UK Ltd.

General Information
Number of Employees: 33 (As of 12/31/2023)
Outstanding Shares: 32,460,579 (As of 3/1/2024)
Shareholders: 37
Stock Exchange: NASD
Federal Tax Id: 770523891
Fax Number: (302) 655-5049
Email Address: info@capnia.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024